Difference between revisions of "Dosulepine-mianserine"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{Drugswitch | from = dosulepine | to = mianserine | stop = * '''Before day 0:''' gradually reduce dosage of dosulpeine to a maximum of 75 mg/day. * '''Day 1:''' reduce dosag...')
(No difference)

Revision as of 12:11, 6 May 2009

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine

Switch medication from dosulepine to mianserine.[1] [2]

Nietinrijdenbord.png Stop dosulepine
  • Before day 0: gradually reduce dosage of dosulpeine to a maximum of 75 mg/day.
  • Day 1: reduce dosage of dosulepine to 50 mg/day.
  • Day 3: reduce dosage of dosulepine to 25 mg/day.
Eenrichtingbord.png Start mianserine

Caution is necessary.

  • Day 1: simultaneously start administration of mianserine in a low dosage of 30 mg/day.
  • Day 8: stop administration of dosulepine and continue administration of mianserine.
  • If necessary, increase dosage of mianserine.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.